Agios Pharmaceuticals | AGIO - Operating Profit


Agios Pharmaceuticals reported $-110.02M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Arrowhead Research USD -141.26M 182.07M Mar/2026
Astellas Pharma JPY 48.57B 85.97B Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Exelixis USD 251.34M 15.43M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026